These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 22010023)

  • 1. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
    Miller TW; Balko JM; Arteaga CL
    J Clin Oncol; 2011 Nov; 29(33):4452-61. PubMed ID: 22010023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
    Miller TW; Rexer BN; Garrett JT; Arteaga CL
    Breast Cancer Res; 2011; 13(6):224. PubMed ID: 22114931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine resistance: what do we know?
    Miller TW
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
    Fox EM; Arteaga CL; Miller TW
    Front Oncol; 2012; 2():145. PubMed ID: 23087906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
    Miller TW; Hennessy BT; González-Angulo AM; Fox EM; Mills GB; Chen H; Higham C; García-Echeverría C; Shyr Y; Arteaga CL
    J Clin Invest; 2010 Jul; 120(7):2406-13. PubMed ID: 20530877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
    Lee KM; Guerrero-Zotano AL; Servetto A; Sudhan DR; Lin CC; Formisano L; Jansen VM; González-Ericsson P; Sanders ME; Stricker TP; Raj G; Dean KM; Fiolka R; Cantley LC; Hanker AB; Arteaga CL
    Nat Commun; 2020 Oct; 11(1):5488. PubMed ID: 33127913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
    Saatci O; Huynh-Dam KT; Sahin O
    J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
    Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
    Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
    Nunnery SE; Mayer IA
    Drugs; 2020 Nov; 80(16):1685-1697. PubMed ID: 32894420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
    Yang W; Hosford SR; Traphagen NA; Shee K; Demidenko E; Liu S; Miller TW
    FASEB J; 2018 Mar; 32(3):1222-1235. PubMed ID: 29127189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Vasan N; Toska E; Scaltriti M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x3-x11. PubMed ID: 31859348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.